Grant: Op Grant: Analyses of Existing Canadian Cohorts & Databases - Cancer Control
McGill University
$48,000.00
Personalized medicine using registry cohort data: Developing an adaptive treatment strategy to prevent and treat graft-versus-host disease
EF 2016-17
Résumé
In our study, we will use data from the Center for International Blood and Transplant Research (CIBMTR) registry to propose an adaptive treatment strategy (ATS) for sequential prevention and treatment of acute graft-versus-host disease, a frequent complication of allogeneic hematopoietic cell transplantation. An ATS is a set of decision rules for allocating treatment where the input includes fixed and time-varying patient characteristics and treatment history and the output is a highly-individualized recommendation at each time a treatment decision is needed. In many situations, information needed to study ATSs in a randomized trial may not be readily available. Thus, analyses of non-randomized data sources are useful for devising ATSs.
Twenty-one Canadian centres provide data to the CIBMITR, making it one of the richest sources of information for studying this frequent complication of the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Our research will address a key question in medical practice: "How can we optimize the sequence of specific treatments for specific patients?", recognizing that clinical trials that test one agent compared to some alternative are often unable to provide the data needed, since treatment effects may vary within subgroups which may not have been considered in the trial; the effect of a patient's time-varying characteristics might affect treatment response; and there may be delayed synergism or antagonism between the treatment examined in the trial and heterogeneous treatments not included in the data capture or analysis.
Programme
Op Grant: Analyses of Existing Canadian Cohorts & Databases - Cancer Control
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
363271
Name
Moodie Erica E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Analyses of existing Canadian cohorts and databases related to Cancer
Projecttitle
Personalized medicine using registry cohort data: Developing an adaptive treatment strategy to prevent and treat graft-versus-host disease
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$48,000
Cihrequipment2
$6,000
Programname2
Op Grant: Analyses of Existing Canadian Cohorts & Databases - Cancer Control
Keyworddelim
Adaptive Treatment Strategies; Cancer Treatment; Graft-Versus-Host Disease; Personalized Medicine; Stem Cell Transplant
Abstract
In our study, we will use data from the Center for International Blood and Transplant Research (CIBMTR) registry to propose an adaptive treatment strategy (ATS) for sequential prevention and treatment of acute graft-versus-host disease, a frequent complication of allogeneic hematopoietic cell transplantation. An ATS is a set of decision rules for allocating treatment where the input includes fixed and time-varying patient characteristics and treatment history and the output is a highly-individualized recommendation at each time a treatment decision is needed. In many situations, information needed to study ATSs in a randomized trial may not be readily available. Thus, analyses of non-randomized data sources are useful for devising ATSs.
Twenty-one Canadian centres provide data to the CIBMITR, making it one of the richest sources of information for studying this frequent complication of the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Our research will address a key question in medical practice: "How can we optimize the sequence of specific treatments for specific patients?", recognizing that clinical trials that test one agent compared to some alternative are often unable to provide the data needed, since treatment effects may vary within subgroups which may not have been considered in the trial; the effect of a patient's time-varying characteristics might affect treatment response; and there may be delayed synergism or antagonism between the treatment examined in the trial and heterogeneous treatments not included in the data capture or analysis.
Competitiondate
201609
Approvedterm2
1 yr 0 mth
Pinamesdelim
Moodie, Erica E
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $48,000~ $6,000~